Regeneron Pharmaceuticals, Inc.
Tarrytown, USA · 11 authors
Regeneron Pharmaceuticals, Inc. (Tarrytown, USA): 11 authors and 3 papers, and 1 patent family in the de novo peptide sequencing catalog.
Departments
- Department of Analytical Chemistry
Papers (3)
- Proteogenomics and de novo sequencing based approach for neoantigen discovery from the immunopeptidomes of patient CRC liver metastases using Mass Spectrometry (2020, The Journal of Immunology)
- Lys-Sequencer: An algorithm for de novo sequencing of peptides by paired single residue transposed Lys-C and Lys-N digestion coupled with high-resolution mass spectrometry (2020, Rapid Communications in Mass Spectrometry)
- Paired single residue‐transposed Lys‐N and Lys‐C digestions for label‐free identification of N‐terminal and C‐terminal MS/MS peptide product ions: ultrahigh resolution Fourier transform ion cyclotron resonance mass spectrometry and tandem mass spectrometry for peptide de novo sequencing (2015, Rapid Communications in Mass Spectrometry)
Patents (1)
- US20240153587A1 Workflow to assign putative source to de novo peptide sequence ↗ (Regeneron Pharmaceuticals, Inc., priority 2021-03-11, pending)
Patent families this institution was the original assignee of.